All In Biotech

Drug Trial Radar · NCT06623526

Clinical Trial to Evaluate the PK Interactions of YHR2402 Monotherapy and YHR2402 and YHR2403 Co-Administration in Healthy Volunteers

An Open-label, Randomized, Fasting, Single-Crossover Study to Compare the Pharmacokinetic Interactions and Safety of YHR2402 Monotherapy and YHR2402 and YHR2403 Co-Administration in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Nov 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Oct 4, 2024

Primary completion

Nov 6, 2024

Study completion Nov 11, 2024

Sponsor

Lead sponsor
Yuhan CorporationIndustry
Sponsor type
Industry
First posted
Oct 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

An open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetic interactions and safety after co-administration of YHR2402 and YHR2403 compared to the administration of YHR2402 independently in healthy subjects

Conditions

  • Healthy Volunteers

Interventions

  • YHR2402Drug

    Test Drug: YHR2402

  • YHR2402+YHR2403Drug

    Test Drug: YHR2402+YHR2403

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the plasma drug concentration-time curve [AUCt]Time frame: 0-96 hours
  2. Maximum plasma concentration [Cmax]Time frame: 0-96 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jeonbuk National University Hospital

    Jeonju, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.